Overview

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

Status:
Completed
Trial end date:
2016-04-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Azilsartan medoxomil